Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: LonZim, Lees Foods, blinkx ...

Wed, 27th May 2009 07:59

Zimbabwe-focused investment company LonZim said it is well-placed to benefit from any upturn in the southern African country's economy after investing in several sectors in the six months to February 28.The company posted a pre-tax loss of £911,000 as it invested in telecoms, aviation and hotel sectors."We are positive that the investment potential in Zimbabwe remains strong and that Zimbabwe has a very bright future as it looks to re-establish its presence as one of the major economies on the African continent," said chairman David Lenigas.Scottish cake and sweet supplier Lees Foods saw profits fall sharply in 2008 as it felt the impact of the collapse of the retail chain Woolworths and high raw material, power and distribution costs.Underlying pre-tax profits fell to £402,000 from £721,000 the previous year even as turnover climbed 8% to £16.1m."The fall in profits was primarily a result of a bad debt provision of £69,000 which was owed to the company by Woolworths and a significant increase in raw materials, power and distribution costs," Lees said.The board is recommending the dividend be maintained at 6.7p a share.Video search engine specialist blinkx has signed an agreement with US sport site FOXSports.com to add almost 1,000 video clips of sporting contests to its searchable video library. Globus Maritime saw gross revenues of $11.8m against $24m in the same period last year, while EBITDA was $7m against $18.8m.AIM-listed Africa-focused gas company Gasol has successfully raised £1m through a placing of shares with two of its principal shareholders, African Gas Development Corporation and Afren.Shares in Vyke Communications were marked lower Wednesday after the company said it issued 0.26m shares to settle supplier invoices totalling 1.75m Norwegian kroner. The newly issued shares represent 0.4% of Vyke's existing issued share capital.Smoker's cough treatment specialist Synairgen has raised £6.35m through a placing and subscription at 17p per share. The proceeds will finance two planned Phase IIa inhaled interferon beta studies in asthma and COPD.Bus maker Optare slipped into a loss £12m in 2008 reflecting costs of integrating two new businesses in difficult trading conditions. Turnover for the year was £49.2m (pro forma £82.4m) and loss from operations was £4.0m (pro forma £3.0m). Programme maker Shed Media has appointed Heather Rabbatts, Millwall FC's executive deputy chairman, as its new chairman. Coline McConville, who sat on the board of HBOS until early this year, and Marc Watson, from BT, are also joining as non-execs. Celebrity agent Formation Group saw profit before tax edge up to £1.83m in the six months ended 28 February from £1.76m a year ago on revenue from continuing operations of £18.8 versus £12.8m last time.The shares rallied yesterday after the group, whose clients include Simon Cowell and TV presenters Ant and Dec, confirmed it has received indications of interest from private equity group Gresham over 'certain parts' of the business. IFA Cavanagh's underlying profits fell to £779,000 (2007: £1.61m) on revenue of £17.5m (2007: £16.6m)in 2008. " Against a backdrop of what has probably been the most volatile period experienced in the financial markets since the 1930s, I consider this to be a satisfactory performance," chairman Paul Sinnet said.Powered glass specialist Romag posted an underlying loss of £1.3m in the half -year to March in what the company describes as the toughest conditions it has seen for 60 years. Unless conditions turned in the next few weeks it is unlikely it will be able to repeat the strong performance in sales and profits achieved in the second half of last year. Interim sales were 12% down at £10.2m, though a £2.7m currency hedging gain enabled it post a £1.1m profit.
More News
8 Sep 2020 19:32

IN BRIEF: Synairgen Reports Promising Findings From SNG001 Trial

IN BRIEF: Synairgen Reports Promising Findings From SNG001 Trial

Read more
8 Sep 2020 15:16

Synairgen upbeat on latest data from SNG001 trials

(Sharecast News) - Respiratory drug discovery and development company Synairgen announced positive data from the interim analysis of its exploratory phase 2 clinical trial of inhaled 'SNG001' on Tuesday, in chronic obstructive pulmonary disease (COPD) patients with a confirmed respiratory viral infection.

Read more
21 Jul 2020 15:51

IN BRIEF: Synairgen Moving "Rapidly" To Get SNG001 Over Line

IN BRIEF: Synairgen Moving "Rapidly" To Get SNG001 Over Line

Read more
20 Jul 2020 20:23

COVID SCIENCE-Multiple vaccine candidates show early promise; inhaled interferon helps severe COVID-19 patients

By Nancy LapidJuly 20 (Reuters) - The following is a brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.Early tests of COVID-19 ...

Read more
20 Jul 2020 16:55

LONDON MARKET CLOSE: FTSE 100 Lags Despite Encouraging Vaccine News

LONDON MARKET CLOSE: FTSE 100 Lags Despite Encouraging Vaccine News

Read more
20 Jul 2020 11:54

Synairgen Shares Soar On Positive Trial Results For Covid-19 Treatment

Synairgen Shares Soar On Positive Trial Results For Covid-19 Treatment

Read more
20 Jul 2020 09:10

REFILE-UPDATE 2-Synairgen soars after drug shows promise in COVID-19 cases

(Refiles to correct spelling in the media identifier)* Shares hit all-time high on Monday* Company's drug cuts risk of severe COVID-19 by 79%* Some researchers caution on enthusiasmBy Aakash BJuly 20 (Reuters) - Synairgen shares rose almost sixfold ...

Read more
20 Jul 2020 09:10

UPDATE 2-Synairgen soars after drug shows promise in COVID-19 cases

* Shares hit all-time high on Monday* Company's drug cuts risk of severe COVID-19 by 79%* Some researchers caution on enthusiasm (Recasts, adds comment from CEO and academic expert)By Aakash BJuly 20 (Reuters) - Synairgen shares rose almost sixfold...

Read more
20 Jul 2020 09:10

UPDATE 1-Synairgen shares soar as drug shows lower risk of severe COVID-19 cases

(Adds details on the trial, shares)July 20 (Reuters) - Synairgen Plc said on Monday its drug helped reduce the risk of severe cases in hospitalised patients with COVID-19, according to data from a trial of more than 100 people in the United Kingdo...

Read more
20 Jul 2020 07:56

Europe open: Stocks reverse early losses, healthcare leads

(Sharecast News) - Stocks have recovered from early selling following news that European Union leaders meeting in Brussels had made progress on the terms for a reconstruction fund.

Read more
20 Jul 2020 07:56

Synairgen's drug shows reduced risk of severe disease in COVID-19 patients

July 20 (Reuters) - Synairgen Plc said on Monday its drug helped reduce the risk of developing severe diseases in hospitalised COVID-19 patients, according to data from a trial of more than 100 people in the United Kingdom.The trial, which used in...

Read more
20 Jul 2020 07:20

Synairgen treatment reduces risk of 'severe' Covid-19 by 79%

(Sharecast News) - Synairgen's Covid-19 treatment sharply reduced the risk of patients developing severe forms of the illness provoked by the novel coronavirus, clinical trials showed.

Read more
22 Jun 2020 16:09

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
18 Jun 2020 17:59

IN BRIEF: Synairgen Expands Home Setting Trial Of Inhaled SNG001

IN BRIEF: Synairgen Expands Home Setting Trial Of Inhaled SNG001

Read more
18 Jun 2020 09:12

Synairgen expands Covid-19 trial nationwide

(Sharecast News) - Synairgen is to expand trials of a potential treatment for Covid-19 nationally, the respiratory drug specialist said on Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.